Rimegepant
Rimegepant.svg
Clinical data
Trade namesNurtec ODT, Vydura
Other namesBHV-3000, BMS-927711
AHFS/Drugs.comMonograph
MedlinePlusa620031
License data
Routes of
administration
By mouth
Drug classcalcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
  • [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC28H28F2N6O3
Molar mass534.568 g·mol−1
3D model (JSmol)
  • N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
  • InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
  • Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N

Rimegepant, sold under the brand name Nurtec ODT among others, is a medication for the acute treatment of migraine with or without aura in adults and preventative treatment of episodic migraine in adults.[2][3]

Taken by mouth to dissolve on or under the tongue,[4] rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It works by blocking CGRP receptors.

In the United States, rimegepant was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021.[3] It is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut.[5][2] During March 2021, Nurtec ODT obtained approval from the United Arab Emirates and Israel.[6][7][8]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.[9]

History

Originally discovered at Bristol-Myers Squibb,[10] rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020.[11] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches.[2]

Society and culture

Legal status

On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine.[12] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC.[12] Rimegepant was approved for medical use in the European Union in April 2022.[1]

References

  1. ^ a b "Vydura EPAR". European Medicines Agency (EMA). 22 February 2022. Retrieved 11 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ a b c "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Retrieved 19 March 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ a b "Nurtec ODT Prescribing Information" (PDF). FDA.gov. U.S. Food and Drug Administration. June 2021.((cite web)): CS1 maint: url-status (link)
  4. ^ "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Retrieved 19 March 2020.
  5. ^ "Nurtec ODT: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 28 February 2020.
  6. ^ "Biohaven Pharma's (BHVN) NURTEC ODT Approved In Israel For Acute Treatment Of Migraine". StreetInsider.com. Retrieved 3 June 2021.
  7. ^ "Nurtec ODT: Treatment and Prevention of Migraine? And How to Get It". Migraine Again. 14 April 2021. Retrieved 3 June 2021.
  8. ^ "Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine". Biohaven Pharmaceuticals. Retrieved 3 June 2021.
  9. ^ Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968. S2CID 26523013.
  10. ^ "Rimegepant - Biohaven Pharmaceuticals Holding Company". Adis Insight. Springer Nature Switzerland AG.
  11. ^ "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020 – via PR Newswire.
  12. ^ a b "Vydura: Pending EC decision". European Medicines Agency (EMA). 24 February 2022. Retrieved 27 February 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.